New hope for kids: drug may block deadly viruses after transplant
NCT ID NCT07488728
First seen Mar 24, 2026 · Last updated May 18, 2026 · Updated 9 times
Summary
This study tests whether the drug letermovir can prevent serious viral infections in children with EBV-related blood disorders who receive a stem cell transplant. About 80 children will be enrolled. The goal is to see if letermovir reduces infections like CMV and EBV and improves overall transplant success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED T/NK-CELL LYMPHOPROLIFERATIVE DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Children's Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.